Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024 07:30 ET
|
Wugen
Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET
June 13, 2024 10:13 ET
|
Pressure BioSciences, Inc.
Pressure BioSciences, Inc. to Host Business and Financial Update
Investor Call on Wednesday, June 19th at 4:30pm ET
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Investment Opportunity: PlantForm Corporation Seeks $25M to Accelerate Plant-Based Medical Breakthroughs
June 12, 2024 14:40 ET
|
US Capital Global
San Francisco, California, USA, June 12, 2024 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an SEC-registered affiliate of renowned global financial group US Capital Global, is pleased to...
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
June 12, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024 07:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
June 11, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Cell Culture Market Is Expected To Reach A Revenue Of USD 80.3 Bn By 2033, At 11.0% CAGR: Dimension Market Research
June 10, 2024 10:53 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Cell Culture Market size is expected to reach USD 31.4 billion by 2024 and is further anticipated to reach USD 80.3 billion...
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 10, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
June 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements